Using proprietary protein evolution platforms and intracellular (iHuMab) and extracellular (eHuMab) genetic selection systems, Abzyme Therapeutics LLC is organized around generating and developing full-sized human monoclonal antibodies for treating a broad range of diseases. The firm has the capabilities of generating a highly diversified human antibody repertoire and establishing a tightly regulated selection system to isolate a single antigen-specific antibody-producing clone from billions. Abzyme Therapeutics is developing a pipeline of novel, targeted human monoclonal antibodies for the treatment of Alzheimerâs disease, cancer, autoimmune diseases, and infectious diseases. Led by an interdisciplinary team of successful industry professionals, Abzyme is introducing a pioneer technology to generate human monoclonal antibodies and exploit the enormous potential of antibody-based medicines.
